Telix, Invicro further AI partnership

By staff writers

June 15, 2022 -- Telix Pharmaceuticals and Invicro have furthered their partnership to develop an artificial intelligence (AI) platform that will be called TelixAI for Telix's prostate-specific membrane antigen (PSMA)-PET imaging agent, Illuccix (gallium-68 gozetotide).

TelixAI will boost the efficiency and reproducibility of clinicians' imaging interpretations by categorizing healthy versus abnormal tracer uptake, according to the firm. The company is highlighting TelixAI at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Vancouver.

In other Telix news, Illuccix is now available in 139 U.S. pharmacies that are part of the Jubilant Radiopharma Network, it said.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking